Outlook Therapeutics, Inc. OTLK 深 滬
已收盤 08-07 16:00:00 美东时间
1.02
+0.048
+4.88%
華盛通- 最 高1.04
- 今 開0.9861
- 成交量 455.93万股
- 最 低 0.95
- 昨 收 0.9725
- 總市值 1.91亿
- 52周最高 3.39
- 市盈率 靜 --
- 換手率 2.44%
- 52周最低 0.1611
- 委 比 80.33%
- 總股本 1.87亿
- 歷史最高 219.20
- 量 比 0.60
- 振 幅 9.25%
- 歷史最低 0.1611
- 每 手 1
- 風險率 0.67%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | ITG、Bending Spoons获多家大行首予买入评级；瑞银下调微软目标价从510美元降至480美元
今日重点评级关注：BTIG：上调Outlook Therapeutics"买入"评级，目标价4美元；TD Cowen：维持Nakamoto"买入"评级，目标价从1美元升至17美元
07-28 11:34
Outlook gains approval for ophthalmic bevacizumab for wet AMD
The US FDA has approved Outlook Therapeutics' (OTLK) Lytenava (bevacizumab-vikg) for wet AMD. Lytevana is the first ophthalmic bevacizumab approved for the condition. It is expected to launch by the e...
07-25 03:20
Outlook Therapeutics Says FDA Approves LYTENAVA For Treatment Of Neovascular Age-Related Macular Degeneration, Commonly Known As Wet AMD
Landmark FDA Approval Is an Important Milestone in Retina Care, Bringing Patients and Physicians an Ophthalmic Bevacizumab Developed Specifically for the Eye Following Years of Rigorous Clinical and Regulatory Evaluation Company Launches Commercial Franchise Positioned to Establish a New Standard as...
07-25 02:41
Outlook Therapeutics Announces LYTENAVA™ FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMD
Outlook Therapeutics' LYTENAVA, an FDA-approved ophthalmic bevacizumab, becomes the first specifically developed for intravitreal administration to treat wet AMD. The approval marks a significant milestone in retina care, offering a purpose-built formulation with rigorous clinical backing and manufacturing consistency. With anticipated 12 years of market exclusivity under BPCIA, LYTENAVA aims to establish a new standard in the $8.5 billion U.S. r...
07-24 18:40
Why Is Kalaris Therapeutics Stock Gaining Friday?
Kalaris Therapeutics, Inc. (NASDAQ:KLRS) announced expanded data from its Phase 1a single ascending dose trial evaluating TH103 for the treatment of neovascular age-related macular degeneration. Following the announcement, the stock jumped nearly 18%. The clinical-stage biopharmaceutical company sta...
07-18 01:31
Outlook Therapeutics Shareholders Approve Major Capital Changes
The latest update is out from Outlook Therapeutics ( ($OTLK) ). On July 16, 202...
07-17 17:17
美股牛股 | AI基建供应商PENG涨逾25%！季报营收大超预期；金山云升逾11%，受益于小米算力投入激增
AI基建供应商PENG涨逾25%！季报营收大超预期；WULF涨近13%，此前与Anthropic签署20年超级租赁协议；金山云升逾11%，受益于小米算力投入激增>>
07-09 18:44
分析师对多家医疗保健企业观点分歧 涉及Outlook Therapeutics（OTLK）、Praxis Precision Medicines（PRAX）与默沙东（MRK）
近期多家机构分析师对医疗健康板块3只个股发布最新评级及目标价，涉及标的为OTLK、PRAX、MRK。 OTLK：BTIG分析师朱利安·哈里森给出持有评级，目标...
06-30 20:48
Outlook Therapeutics Regains Nasdaq Minimum Bid Compliance
The latest update is out from Outlook Therapeutics ( ($OTLK) ). On February 18,...
06-27 05:54
美股牛股 | LPRO大涨超48%，获保险经纪平台ANV溢价要约收购；OTLK涨超35%
LPRO大涨超48%，获保险经纪平台ANV溢价要约收购；OTLK涨超35%，核心产品许可申请获FDA重新受理；LION涨近14%，奈飞有意收购该公司>>
06-17 15:55
